STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims
<p>The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims</p>